Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane N Winter

Showing results (61-70 of 142) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens, William G Spies, Irene B Helenowski, et al.
Leukemia|August 27, 2022
Response to "The WHO classification of haematolymphoid tumours" (Editorial)Steven H Swerdlow, Elias Campo, Daniel A Arber, et al.
JAMA Oncology|March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical TrialLocke J Bryan, Carla Casulo, Pamela B Allen, et al.
The New England Journal of Medicine|December 14, 2011
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphomaRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
Blood|September 29, 2020
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphomaPamela B Allen, Hatice Savas, Andrew M Evens, et al.
Plos One|March 26, 2013
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivoRichard W Ahn, Susan L Barrett, Meera R Raja, et al.
Cancers|May 14, 2022
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan AreaAlain Mina, Carlos Galvez, Reem Karmali, et al.
British Journal of Haematology|March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphomaRyan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter, David J Inwards, Stewart Spies, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
Pageof 15

Showing results (61-70 of 142) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens, William G Spies, Irene B Helenowski, et al.
Leukemia|August 27, 2022
Response to "The WHO classification of haematolymphoid tumours" (Editorial)Steven H Swerdlow, Elias Campo, Daniel A Arber, et al.
JAMA Oncology|March 17, 2023
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical TrialLocke J Bryan, Carla Casulo, Pamela B Allen, et al.
The New England Journal of Medicine|December 14, 2011
ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphomaRalph M Meyer, Mary K Gospodarowicz, Joseph M Connors, et al.
Blood|September 29, 2020
Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphomaPamela B Allen, Hatice Savas, Andrew M Evens, et al.
Plos One|March 26, 2013
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivoRichard W Ahn, Susan L Barrett, Meera R Raja, et al.
Cancers|May 14, 2022
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan AreaAlain Mina, Carlos Galvez, Reem Karmali, et al.
British Journal of Haematology|March 18, 2014
F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphomaRyan D Gentzler, Andrew M Evens, Alfred W Rademaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter, David J Inwards, Stewart Spies, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 5, 2016
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male SexZheng Zhou, Alfred W Rademaker, Leo I Gordon, et al.
Pageof 15